ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Clinical trials for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR t-cell combo shows promise for tough leukemia
Disease control Recruiting nowThis study tests two different CAR T-cell treatments for children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. One group gets a combination of two types of CAR T-cells (CD19 and CD22), while the other gets one …
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 09:25 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatment…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated May 17, 2026 09:19 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and at…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 09:18 UTC
-
Experimental combo therapy offers new hope for relapsed leukemia patients
Disease control Recruiting nowThis early-stage study tests a two-step treatment for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard therapies. First, patients receive donor immune cells (CAR T cells) followed by a stem cell transplant, then a second dose of donor…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 09:09 UTC
-
New combo therapy offers hope for kids with Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a combination of the targeted drug trametinib with standard chemotherapy drugs (dexamethasone, cyclophosphamide, and cytarabine) in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find t…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New CAR T-Cell therapy trial offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis early-stage study is testing a new type of immune cell therapy (CAR T-cells) for children and young adults up to age 21 whose leukemia has returned or not responded to standard treatments. The therapy uses donor immune cells that are specially trained to find and attack leuk…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy aims to tackle tough blood cancers in kids
Disease control Recruiting nowThis early-phase study tests a drug called venetoclax combined with standard chemotherapy for children, teens, and young adults with aggressive blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and understand side effects. About 30 part…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Andrew E. Place, MD • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for kids with Hard-to-Treat blood cancers: drug cocktail trial launches
Disease control Recruiting nowThis study tests a combination of two targeted drugs (ruxolitinib and venetoclax) plus chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find the safest dose and see how well the drugs shri…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Engineered immune cells take on deadly T-Cell cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR T cells for people with T-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to better attack the cancer. The tri…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New combo therapy aims to keep cancer-fighting cells from burning out
Disease control Recruiting nowThis study looks at whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in people with relapsed or refractory B-cell acute lymphoblastic leukemia. About 213 children and young adults will be randomly assigned to receive either sta…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells, modified to target and kill cancer cells. The trial will first fi…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 01, 2026 15:59 UTC